Richard I Eisenstadt Altimmune, Inc. (ALT) insider trading activity

Richard I Eisenstadt is Chief Financial Officer of Altimmune, Inc.. Currently has a direct ownership of 45,012 shares of ALT, which is worth approximately $349,293. The most recent transaction as insider was on Jan 31, 2024, when has been sold 4,621 shares (Common Stock, par value $0.0001) at a price of $2.69 per share, resulting in proceeds of $12,430. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 45K

0% 3M change

88.85% 12M change

Total Value Held $349,293

Richard I Eisenstadt Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 31 2024	BUY Grant, award, or other acquisition	$12,430 $2.69 p/Share	4,621 Added 9.31%	45,012 Common Stock, par valu...
Jan 30 2024	SELL Payment of exercise price or tax liability	$21,315 $9.8 p/Share	2,175 Reduced 5.11%	40,391 Common Stock, par valu...
Jan 30 2024	BUY Exercise of conversion of derivative security	-	9,275 Added 17.89%	42,566 Common Stock, par valu...
Dec 29 2023	SELL Payment of exercise price or tax liability	$34,245 $11.25 p/Share	3,044 Reduced 8.38%	33,291 Common Stock, par valu...
Dec 29 2023	BUY Exercise of conversion of derivative security	-	12,500 Added 25.6%	36,335 Common Stock, par valu...
Jul 31 2023	BUY Grant, award, or other acquisition	$5,128 $2.81 p/Share	1,825 Added 7.11%	23,835 Common Stock, par valu...
Mar 24 2023	BUY Open market or private purchase	$43,099 $4.31 p/Share	10,000 Added 31.24%	22,010 Common Stock, par valu...
Jan 31 2023	BUY Grant, award, or other acquisition	$11,966 $10.21 p/Share	1,172 Added 8.89%	12,010 Common Stock, par valu...
Dec 31 2022	SELL Payment of exercise price or tax liability	$49,810 $16.45 p/Share	3,028 Reduced 21.84%	10,838 Common Stock, par valu...
Dec 31 2022	BUY Exercise of conversion of derivative security	-	12,500 Added 47.41%	13,866 Common Stock, par valu...
Jul 31 2022	BUY Grant, award, or other acquisition	$9,371 $6.86 p/Share	1,366 Added 50.0%	1,366 Common Stock, par valu...

Also insider at

AYTU

AYTU BIOPHARMA, INC Healthcare

Chief Financial Officer

RIE